✦ LIBER ✦

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

✍ Scribed by Janku, F.; Wheler, J. J.; Westin, S. N.; Moulder, S. L.; Naing, A.; Tsimberidou, A. M.; Fu, S.; Falchook, G. S.; Hong, D. S.; Garrido-Laguna, I.

Book ID: 111674550
Publisher: American Society of Clinical Oncology
Year: 2012
Tongue: English
Weight: 257 KB
Volume: 30
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2011.36.1196

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PIK3CA Mutations in Patients with Advanc

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

✍ Janku, F.; Tsimberidou, A. M.; Garrido-Laguna, I.; Wang, X.; Luthra, R.; Hong, D 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 646 KB

253 Screening for PIK3CA, RAS, and RAF m

253 Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors

✍ F. Janku; A.M. Tsimberidou; I. Garrido-Laguna; D.S. Hong; A.M. Naing; G.S. Falch 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

The PI3K/AKT/MTOR Signaling Pathway: The

The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer

✍ Huemer, Florian; Bartsch, Rupert; Gnant, Michael 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 355 KB

PIK3CA Mutation H1047R Is Associated wit

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

✍ Janku, F.; Wheler, J. J.; Naing, A.; Falchook, G. S.; Hong, D. S.; Stepanek, V. 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 494 KB

246 Aberrations in PIK3CA, PTEN, and MAP

246 Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 Patients and Experience with Early-phase Protocols with PI3K/AKT/mTOR Inhibitors

✍ Janku, F.; Hong, D.S.; Fu, S.; Piha-Paul, S.A.; Naing, A.; Falchook, G.S.; Tsimb 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

A detailed immunohistochemical analysis

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features

✍ Levidou, Georgia 📂 Article 📅 2013 🏛 Spandidos Publications Ltd 🌐 English ⚖ 941 KB